outpatient |
||||
|
News for 20-May-26 Source: MedicineNet Prevention and Wellness General Source: MedicineNet Prevention and Wellness General Source: MedicineNet Prevention and Wellness General Source: MedicineNet Prevention and Wellness General |
The Best outpatient websiteAll the outpatient information you need to know about is right
here. Presented and researched by http://www.md-news.net. We've searched
the information super highway far and wide to provide you with the
best outpatient site on the internet today. The links below will
assist you in your efforts to find the information that you are looking
for about
outpatient
Netscape Corporation has created the best known secure server technologies. It uses a security protocol called Secure Sockets Layer (SSL) that provides data encryption, server authentication, message integrity and optional client authentication for a TCP/IP connection. When a client seeking to purchase outpatient connects with a secure server, they exchange a *handshake* which initiates a secure session. With this protocol, the same server system can run both secure and unsecured web servers simultaneously. This means an outpatient organization or company can provide some information to all users using no security, and other information that is secured. For example, a business that sells outpatient online can have its storefront (merchandise catalog) unsecured, but ordering and payment forms can be secure. Why are these developments important? As the Internet becomes a way to buy and sell outpatient products and services, financial transactions become essential. Right now, most outpatient transactions involve the exchange of credit card information, either directly over the network, or by phone, to complete a transaction initiated online. Eventually, you will be able to use cash as well as credit, directly over the network. There are two basic kinds of digital cash, anonymous cash and identified cash. Anonymous cash is just like paying for outpatient with paper cash but it also carries no information about the person making the transaction, and leaves no transaction trail. You create it by using numbered bank accounts and blind signatures. Identified cash, on the other hand, contains information revealing the identity of the person who withdrew it from the bank. Like credit card transactions, identified cash can be tracked as it moves through the system and involves fully identified accounts and non-blind signatures. Whether you use digital cash when purchasing outpatient is entirely up to you. We suggest you employ the purchasing avenues available from the outpatient supplier we recommend. outpatient
Shopping online for outpatient offers lots of benefits that you won't find shopping in a outpatient store or catalogue. For example, the Internet is always open - seven days a week, 24 hours a day. Many outpatient bargains can only be found online. Shopping on the Internet is no less safe than shopping in a store or by mail. Keep the following tips in mind to help ensure that your outpatient shopping experience is a safe one. Drug Offers Hope to Cancer Patients by: ARA Content
(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own blood supply. But opinion was still divided in the scientific community. Angiogenesis itself is a natural and necessary physiological function, which refers to the process by which new blood vessels form and develop. In its pathological form, however, angiogenesis is also implicated in the progression of more than 20 different diseases, including cancer. In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of new blood vessels, without which cancerous cells are starved and tumors cannot grow. In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance. Indeed, the scientific community now believes that more than 90 percent of all cancer cases are angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and more than 100 research organizations and companies are currently developing angiogenesis-blocking drugs. Ęterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase ll trial in multiple myeloma, a form of blood cancer. Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials. Further advantages of Neovastat are that it is orally administered, which makes it convenient for patients who must receive treatment on a long-term basis, and it may be taken in association with standard therapies such as chemotherapy. Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without suffering from the often debilitating side-effects that some treatments can produce. Ęterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II trials with 125 patients in the United States, Canada and Europe. This trial should be completed in early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005. Once the clinical trials are complete, health authorities in various countries can then assess these results and make decisions on approval.
|
|||
|
http://www.medmeet.com/ |
||||
| medical mailings MD Meet Go Antiques |